Hazardous Drugs: Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings and Managing Hazardous Drug Exposures: Information for Healthcare Settings

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Centers for Disease Control and Prevention [Docket No. CDC–2020–0046; NIOSH–233–C] AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: General notice. SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the following final documents are available in the docket and on the NIOSH website: Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings and Managing Hazardous Drug Exposures: Information for Healthcare Settings . DATES: The documents announced in this notice are available on April 27, 2023. ADDRESSES: The documents announced in this notice are available in the docket at www.regulations.gov and through the NIOSH Hazardous Drug Exposures in Healthcare website at https://www.cdc.gov/​niosh/​topics/​hazdrug/​default.html . FOR FURTHER INFORMATION CONTACT: Jerald Ovesen, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C15, Cincinnati, OH 45226; Telephone: (513) 533–8472 (not a toll-free number); Email: jovesen@cdc.gov . SUPPLEMENTARY INFORMATION: This notice is organized as follows: I. Public Participation II. Background III. Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings A. Section II. Purposes 1. Appli…